Recent strategies for the chemotherapy of visceral leishmaniasis

Current Opinion in Infectious Diseases

Volumn 12, Issue 6, 1999, Pages 559-564

  Loiseau, Philippe M ^a   Bories, Christian ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; DRUG CARRIER; IMMUNOMODULATING AGENT; MILTEFOSINE; PAROMOMYCIN;

CLINICAL TRIAL; HUMAN; REVIEW; VISCERAL LEISHMANIASIS;

EID: 0033369324     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199912000-00006     Document Type: Review

References (50)

1. 1 Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, et al. Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans Roy Soc Trop Med Hyg 1995; 89:159-162.
2. 2 Manuel de Lutte contre la leishmaniose viscérale. W.H.O. WHO/Leish/ 96.39, 1996.
3. 3 Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997; 10:298-319.
4. 4 Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, et al. Clinicoepidemiologic characteristics prognostic factors and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 1998; 58:436-443.
5. 5 Berhe N, Hailu A, Wolday D, Negesse Y, Cenini P, Frommel D. Ethiopian visceral leishmaniasis patients co-infected with human immunodeficiency virus. Trans Roy Soc Trop Med Hyg 1995; 89:205-207.
6. 6 Davidson RN. Practical guide for the treatment of leishmaniasis. Drugs 1998; 56:1009-1018. This review is intended to assist the clinician in choosing treatment and in using unfamiliar drugs effectively and safely.
7. 7 Khalil EA, El Hassan AM, Zijlstra EE, Hashim FA, Ibrahim ME, Ghalib HW, Ali MS. Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond. Ann Trop Med Parasitol 1998; 92:151-158. Large scale clinical trial in the East-African focus of L. donovani with very low level of therapeutic failure after stibogluconate treatment.
8. 8 Aronson NE, Wortmann GW, Johnson SC, Jackson JE, Gasser RA, Magill AJ, et al. Safety and efficacy of intravenous sodium stibogluconate in the treatment of leishmaniasis: recent US military experience. Clin Infect Dis 1998; 27:1457-1464.
9. 9 Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, et al. A cluster of cases of severe cardiotoxicity among kala-azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am J Trop Med Hyg 1998; 59:139-143.
10. 10 Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, Hassan SM, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observation study of 80 cases. Ann Trop Med Parasitol 1998; 92:561-569.
11. 11 Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: a comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother 1998; 42:2722-2725.
12. 12 Carter KC, Baillie AJ, Mullen AB. The cured immune phenotype achieved by treatment of visceral leishmaniasis in the BALB/c mouse with a nonionic surfactant vesicular formulation of sodium stibogluconate does not protect against reinfection. Clin Diagn Lab Immunol 1999; 6:61-65.
13. 13 Roberts WL, Mcmurray WJ, Rainey PM. Characterization of the antimonial antileishmanial agent meglumine antimonate (Glucantime®). Antimicrob Agents Chemother 1998, 42:1076-1082.
14. 14 Ephros M, Bitnun A, Shaked P, Waldman E, Zilberstein D. Stage-specific activity of pentavalent antimony against Leishmania donovani axenic amastigotes. Antimicrob Agents Chemother 1999; 43:278-282.
15. 15 Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother 1998, 42:3097-3102.
16. 16 Durand R, Paul M, Pratlong F, Rivollet D, Dubreuil-Lemaire ML, Houin R, et al. Leishmania infantum: lack of parasite resistance to amphotericin B in a clinically resistant visceral leishmaniasis. Antimicrob Agents Chemother 1998, 42:2141-2143.
17. 17 Mbongo N, Loiseau PM, Billion MA, Robert-Gero M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob Agents Chemother 1998, 42:352-357.
18. 18 Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998, 55:585-612.
19. 19 Berman JD, Badaro R, Thakur CP, Wasunna KM, Behbehani K, Davidson R, et al. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries. Bull World Health Organ 1998; 76:25-32.
20. 20 Sundar S, Goyal AK, More DK, Singh MK, Murray HW. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin B lipid complex. Ann Trop Med Parasitol 1998; 92:755-764.
21. 21 Coukell AJ, Brogden RN. Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis. Drugs 1998; 55:585-612.
22. 22 Brogden RN, Goa KL, Coukell AJ. Amphotericin B colloidal dispersion: a review of its use against systemic fungal infections and visceral leishmaniasis. Drugs 1998; 56:365-383.
23. 23 Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL. Activity of a heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob Agents Chemother 1999; 43:390-392.
24. 24 Jha TK, Olliaro P, Thakur CPN, Kanyok TP, Singhania BL, Singh IJ, et al. Randomized controlled trial of aminosidine (paromomycin) vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. Br Med J 1998; 316:1200-1205.
25. 25 Olliaro P, Jha TK. Clarification of comments on trial of aminosidine in visceral leishmaniasis. Br Med J 1998, 317:1250-1250.
26. 26 Williams D, Mullen AB, Baillie AJ, Carter KC. Comparison of the efficacy of free and non-ionic-surfactant vesicular formulations of paromomycin in a murine model of visceral leishmaniasis. J Pharm Pharmacol 1998; 50:1351-1356.
27. 27 Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, et al. Trial of oral miltefosine for visceral leishmaniasis. Lancet 1998; 352:1821-1823. This is the first evaluation of safety, tolerance and efficacy of miltefosine in patients with visceral leishmaniasis, with encouraging results.
28. 28 Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelièvre A, Grousson D, Kubar J. Short-and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 1998; 42:654-658.
29. 29 Gangneux JP, Dullin M, Sulahian A, Garin YJ, Derouin F. Experimental evaluation of second-line oral treatments of visceral leishmaniasis caused by Leishmania infantum. Antimicrob Agents Chemother 1999; 43:172-174.
30. 30 Al-Abdely HM, Graybill JR, Bocanegra R, Najvar L, Montalbo E, Regen SL, Melby PC. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother 1998, 42:2542-2548.
31. 31 Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Sanchez G, et al. Treatment of chronic Chagas' disease with itraconazole and allopurinol. Am J Trop Med Hyg 1999; 59:133-138.
32. 32 Angarano G, Maggi P, Coppola SL, Cavaliere RL. Itraconazole as maintenance therapy for visceral leishmaniasis in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1998; 17:365-367.
33. 33 Ginel PJ, Lucena R, Lopez R, Molleda JM. Use of allopurinol for maintenance of remission in dogs with leishmaniasis. J Small Anim Pract 1998; 39:271-274.
34. 34 Chakrabarti G, Basu A, Manna PP, Mahato SB, Mandal NB, Bandyopadhyay S. Indolylquinoline derivatives are cytotoxic to Leishmania donovani promastigotes and amastigotes in vitro and are effective in treating murine visceral leishmaniasis. J Antimicrob Chemother 1999; 43:359-366.
35. 35 Lowe G, Droz AS, Vilaivan T, Weaver GW, Tweedale L, Pratt JM, et al. Cytotoxicity of (2,2′:6′,2″-terpyridine)platinum(II) complexes to Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Med Chem 1999; 42:999-1006.
36. 36 Mesa-Valle CM, Rodriguez-Cabezas MN, Moraleda-Lindez V, Craciunescu D, Sanchez-Moreno M, Osuna A. In vitro and in vivo activity of two Pt(IV) salts against Leishmania donovani. Pharmacology 1998; 57:160-172.
37. 37 Akendengue B, Ngou-Milama E, Laurens A, Hocquemiller R. Recent advances in the fight against leishmaniasis with natural products. Parasite 1999; 6:3-8. The active compounds obtained from some medicinal plant used traditionally worldwide for the treatment of leishmaniasis are reviewed.
38. 38 Kam TS, Sim KM, Koyano T, Toyoshima M, Hayashi M, Komiyama K. Cytotoxic and leishmanicidal aminoglycosteroids and aminosteroids from Holarrhena curtisii. J Nat Prod 1998; 61:1332-1336.
39. 39 Oliva G, Gradoni L, Cortese L, Orsini S, Ciaramella P, Scalone A, et al. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis. Ann Trop Med Parasitol 1998; 92:165-171.
40. 40 Mbongo N, Loiseau PM, Craciunescu DG, Robert-Gero M. Synergistic effect of Ir-(COT)-pentamidine alizarin red and pentamidine, amphotericin B, and paromomycin on Leishmania donovani. Acta Trop 1998; 70:239-245.
41. 41 Sundar S, Singh VP, Sharma S, Makharia MK, Murray HW. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J Infect Dis 1997; 176:1117-1119.
42. 42 Medrano FJ, Rey C, Leal M, Canavate C, Rubio A, Sanchez-Quijano A, et al. Dynamic of serum cytokines in patient with visceral leishmaniasis and HIV-1 co-infection. Clin Exp Immunol 1998; 114:403-407. This paper focuses on the relationship between visceral leishmaniasis and HIV-1 infection with comments on the immunological status of patients.
43. 43 Laguna F, Lopez-Velez R, Pulido F, Salas A, Torre-Cisnero J, Torres E, et al. treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group. AIDS 1999, 18:1063-1069.
44. 44 Daver RT, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, et al. A randomized trial of high versus low doses subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179:849-858.
45. 45 Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: efficacy and mode of action. J Infect Dis 1999; 179:1485-1494.
46. 46 Valladares JE, Riera C, Alberola J, Gallego M, Portus M, Cristofol C, et al. Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum. Vet Parasitol 1998; 75:33-40.
47. 47 Belloli C, Crescenzo G, Carli S, Zaghini A, Mengozzi G, Bertini S, Ormas P. Disposition of antimony and aminosidine combination after multiple sub-cutaneous injections in dogs. Vet J 1999; 157:315-321.
48. 48 Chan C, Yin H, Garforth J, McKie JH, Jaouhari R, Speers P, et al. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs. J Med Chem 1998; 41:148-156.
49. 49 Perez-Victoria JM, Chiquero MJ, Conseil G, Dayan G, Di Pietro A, Barron D, et al. Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. Biochemistry 1999; 38:1736-1743. This is the first time that a biochemical target involved in the drug resistance in Leishmania has led to a rational drug design of inhibitors that having in-vitro activity against parasite growth. This is a study of drug resistance mechanisms, that was performed in order to design specific reversal agents.
50. 50 Balana-Fouce R, Reguera RM, Cubria JC, Ordonez D. The pharmacology of leishmaniasis. Gen Pharmacol 1998; 30:435-443. A review of experimental chemotherapies in leishmaniasis is provided.